NMDA receptor subunits change in the prefrontal cortex of pure-opioid and multi-drug abusers: a post-mortem study

  • Hamidreza Daneshparvar
  • Mitra-Sadat Sadat-Shirazi
  • Monir Fekri
  • Solmaz Khalifeh
  • Ali Ziaie
  • Nasrin Esfahanizadeh
  • Nasim Vousooghi
  • Mohammad-Reza Zarrindast
Original Paper

Abstract

Addiction is a chronic relapsing disorder and is one of the most important issues in the world. Changing the level of neurotransmitters and the activities of their receptors, play a major role in the pathophysiology of substance abuse disorders. It is well-established that N-methyl-d-aspartate receptors (NMDARs) play a significant role in the molecular basis of addiction. NMDAR has two obligatory GluN1 and two regionally localized GluN2 subunits. This study investigated changes in the protein level of GluN1, GluN2A, and GluN2B in the prefrontal cortex of drug abusers. The medial prefrontal cortex (mPFC), lateral prefrontal cortex (lPFC), and orbitofrontal cortex (OFC) were dissected from the brain of 101 drug addicts brains and were compared with the brains of non-addicts (N = 13). Western blotting technique was used to show the alteration in NMDAR subunits level. Data obtained using Western blotting technique showed a significant increase in the level of GluN1 and GluN2B, but not in GluN2A subunits in all the three regions (mPFC, lPFC, and OFC) of men whom suffered from addiction as compared to the appropriate controls. These findings showed a novel role for GluN1, GluN2B subunits, rather than the GluN2A subunit of NMDARs, in the pathophysiology of addiction and suggested their role in the drug-induced plasticity of NMDARs.

Keywords

Addiction Opioid Post-mortem N-Methyl-d-aspartate (NMDA) receptor Prefrontal cortex 

Notes

Acknowledgements

The authors acknowledge the grant support of the legal medicine research center.

Compliance with ethical standards

Conflict of interest

Authors have no conflict of interest to declare.

Supplementary material

406_2018_900_MOESM1_ESM.docx (75 kb)
Supplementary material 1 (DOCX 75 KB)
406_2018_900_MOESM2_ESM.docx (36 kb)
Supplementary material 2 (DOCX 36 KB)
406_2018_900_MOESM3_ESM.docx (37 kb)
Supplementary material 3 (DOCX 36 KB)

References

  1. 1.
    Richard Isralowitz PAF (2016) Mental health and addiction care in the middle east. Springer International Publishing, New YorkCrossRefGoogle Scholar
  2. 2.
    Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3:760–773CrossRefPubMedGoogle Scholar
  3. 3.
    Koob GF, Le Moal M (1997) Drug abuse: hedonic homeostatic dysregulation. Science 278:52–58CrossRefPubMedGoogle Scholar
  4. 4.
    Kaufman E (1976) The abuse of multiple drugs. I. Definition, classification, and extent of problem. Am J Drug Alcohol Abuse 3:279–292CrossRefPubMedGoogle Scholar
  5. 5.
    Kaufman E (1977) Polydrug abuse or multidrug misuse: it’s here to stay. Br J Addict Alcohol Other Drugs 72:339–347CrossRefPubMedGoogle Scholar
  6. 6.
    Meldrum BS (2000) Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 130:1007S–1015SCrossRefPubMedGoogle Scholar
  7. 7.
    Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK et al (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405–496CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Muto T, Tsuchiya D, Morikawa K, Jingami H (2007) Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proc Natl Acad Sci USA 104:3759–3764CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Zhuo M (2009) Plasticity of NMDA receptor NR2B subunit in memory and chronic pain. Mol Brain 2:4CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Glasgow NG, Siegler Retchless B, Johnson JW (2015) Molecular bases of NMDA receptor subtype-dependent properties. J Physiol 593:83–95CrossRefPubMedGoogle Scholar
  11. 11.
    Kendrick SJ, Lynch DR, Pritchett DB (1996) Characterization of glutamate binding sites in receptors assembled from transfected NMDA receptor subunits. J Neurochem 67:608–616CrossRefPubMedGoogle Scholar
  12. 12.
    Cozzoli DK, Goulding SP, Zhang PW, Xiao B, Hu JH, Ary AW et al (2009) Binge drinking upregulates accumbens mGluR5-Homer2-PI3K signaling: functional implications for alcoholism. J Neurosci 29:8655–8668CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Cozzoli DK, Courson J, Wroten MG, Greentree DI, Lum EN, Campbell RR et al (2014) Binge alcohol drinking by mice requires intact group 1 metabotropic glutamate receptor signaling within the central nucleus of the amygdala. Neuropsychopharmacology 39:435–444CrossRefPubMedGoogle Scholar
  14. 14.
    Liddie S, Itzhak Y (2016) Variations in the stimulus salience of cocaine reward influences drug-associated contextual memory. Addict Biol 21:242–254CrossRefPubMedGoogle Scholar
  15. 15.
    Paoletti P (2011) Molecular basis of NMDA receptor functional diversity. Eur J Neurosci 33:1351–1365CrossRefPubMedGoogle Scholar
  16. 16.
    Kauer JA, Malenka RC (2007) Synaptic plasticity and addiction. Nat Rev Neurosci 8:844–858CrossRefPubMedGoogle Scholar
  17. 17.
    Van den Oever MC, Spijker S, Smit AB, De Vries TJ (2010) Prefrontal cortex plasticity mechanisms in drug seeking and relapse. Neurosci Biobehav Rev 35:276–284CrossRefPubMedGoogle Scholar
  18. 18.
    Tzschentke TM (2000) The medial prefrontal cortex as a part of the brain reward system. Amino acids 19:211–219CrossRefPubMedGoogle Scholar
  19. 19.
    Robbins TW, Ersche KD, Everitt BJ (2008) Drug addiction and the memory systems of the brain. Ann N Y Acad Sci 1141:1–21CrossRefPubMedGoogle Scholar
  20. 20.
    LaLumiere RT, Kalivas PW (2008) Glutamate release in the nucleus accumbens core is necessary for heroin seeking. J Neurosci 28:3170–3177CrossRefPubMedGoogle Scholar
  21. 21.
    Peters J, Kalivas PW, Quirk GJ (2009) Extinction circuits for fear and addiction overlap in prefrontal cortex. Learn Mem 16:279–288CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Peters J, LaLumiere RT, Kalivas PW (2008) Infralimbic prefrontal cortex is responsible for inhibiting cocaine seeking in extinguished rats. J Neurosci 28:6046–6053CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Botelho MF, Relvas JS, Abrantes M, Cunha MJ, Marques TR, Rovira E et al (2006) Brain blood flow SPET imaging in heroin abusers. Ann N Y Acad Sci 1074:466–477CrossRefPubMedGoogle Scholar
  24. 24.
    Goldstein RZ, Volkow ND (2002) Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159:1642–1652CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kozlenkov A, Jaffe AE, Timashpolsky A, Apontes P, Rudchenko S, Barbu M et al (2017) DNA methylation profiling of human prefrontal cortex neurons in heroin users shows significant difference between genomic contexts of hyper- and hypomethylation and a younger epigenetic age. Genes 8:152–170CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Christie MJ, Summers RJ, Stephenson JA, Cook CJ, Beart PM (1987) Excitatory amino acid projections to the nucleus accumbens septi in the rat: a retrograde transport study utilizing D[3H]aspartate and [3H]GABA. Neuroscience 22:425–439CrossRefPubMedGoogle Scholar
  27. 27.
    Kelley AE, Domesick VB, Nauta WJ (1982) The amygdalostriatal projection in the rat—an anatomical study by anterograde and retrograde tracing methods. Neuroscience 7:615–630CrossRefPubMedGoogle Scholar
  28. 28.
    Everitt BJ, Morris KA, O’Brien A, Robbins TW (1991) The basolateral amygdala-ventral striatal system and conditioned place preference: further evidence of limbic-striatal interactions underlying reward-related processes. Neuroscience 42:1–18CrossRefPubMedGoogle Scholar
  29. 29.
    Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, Robbins TW (1999) Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann N Y Acad Sci 877:412–438CrossRefPubMedGoogle Scholar
  30. 30.
    Mayer DJ, Mao J, Holt J, Price DD (1999) Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci USA 96:7731–7736CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Zhu H, Brodsky M, Gorman AL, Inturrisi CE (2003) Region-specific changes in NMDA receptor mRNA induced by chronic morphine treatment are prevented by the co-administration of the competitive NMDA receptor antagonist LY274614. Brain Res Mol Brain Res 114:154–162CrossRefPubMedGoogle Scholar
  32. 32.
    Mai JK, Paxinos G (2011) The human nervous system. Elsevier Science, AmsterdamGoogle Scholar
  33. 33.
    Ashabi G, Sadat-Shirazi MS, Khalifeh S, Elhampour L, Zarrindast MR (2017) NMDA receptor adjusted co-administration of ecstasy and cannabinoid receptor-1 agonist in the amygdala via stimulation of BDNF/Trk-B/CREB pathway in adult male rats. Brain Res Bull 130:221–230CrossRefPubMedGoogle Scholar
  34. 34.
    Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217–238CrossRefPubMedGoogle Scholar
  35. 35.
    Fein G, Di Sclafani V, Meyerhoff DJ (2002) Prefrontal cortical volume reduction associated with frontal cortex function deficit in 6-week abstinent crack-cocaine dependent men. Drug Alcohol Depend 68:87–93CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Peters J, De Vries TJ (2012) Glutamate mechanisms underlying opiate memories. Cold Spring Harbor Perspect Med 2:a012088CrossRefGoogle Scholar
  37. 37.
    Bishop SF, Lauzon NM, Bechard M, Gholizadeh S, Laviolette SR (2011) NMDA receptor hypofunction in the prelimbic cortex increases sensitivity to the rewarding properties of opiates via dopaminergic and amygdalar substrates. Cereb Cortex 21:68–80CrossRefPubMedGoogle Scholar
  38. 38.
    Koob GF, Arends MA, Moal ML (2014) Drugs, addiction. Elsevier Science, AmsterdamGoogle Scholar
  39. 39.
    Bobula B, Hess G (2009) Effects of morphine and methadone treatments on glutamatergic transmission in rat frontal cortex. Pharmacol Rep 61:1192–1197CrossRefPubMedGoogle Scholar
  40. 40.
    Zhu H, Jang CG, Ma T, Oh S, Rockhold RW, Ho IK (1999) Region specific expression of NMDA receptor NR1 subunit mRNA in hypothalamus and pons following chronic morphine treatment. Eur J Pharmacol 365:47–54CrossRefPubMedGoogle Scholar
  41. 41.
    Bajo M, Crawford EF, Roberto M, Madamba SG, Siggins GR (2006) Chronic morphine treatment alters expression of N-methyl-d-aspartate receptor subunits in the extended amygdala. J Neurosci Res 83:532–537CrossRefPubMedGoogle Scholar
  42. 42.
    Kozela E, Popik P (2007) A complete analysis of NMDA receptor subunits in periaqueductal grey and ventromedial medulla of morphine tolerant mice. Drug Alcohol Depend 86:290–293CrossRefPubMedGoogle Scholar
  43. 43.
    Herrold AA, Persons AL, Napier TC (2013) Cellular distribution of AMPA receptor subunits and mGlu5 following acute and repeated administration of morphine or methamphetamine. J Neurochem 126:503–517CrossRefPubMedGoogle Scholar
  44. 44.
    Anglin MD, Burke C, Perrochet B, Stamper E, Dawud-Noursi S (2000) History of the methamphetamine problem. J Psychoact drugs 32:137–141CrossRefGoogle Scholar
  45. 45.
    Cisneros IE, Ghorpade A (2014) Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology 85:499–507CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Crocker CE, Purdon SE, Hanstock CC, Lakusta B, Seres P, Tibbo PG (2017) Enduring changes in brain metabolites and executive functioning in abstinent cocaine users. Drug and alcohol dependence 178:435–442CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Hamidreza Daneshparvar
    • 1
  • Mitra-Sadat Sadat-Shirazi
    • 2
    • 3
  • Monir Fekri
    • 2
  • Solmaz Khalifeh
    • 4
  • Ali Ziaie
    • 5
  • Nasrin Esfahanizadeh
    • 6
  • Nasim Vousooghi
    • 2
    • 3
  • Mohammad-Reza Zarrindast
    • 2
    • 7
  1. 1.Legal Medicine Research CenterLegal Medicine OrganizationTehranIran
  2. 2.Iranian National Center for Addiction Studies (INCAS)Tehran University of Medical SciencesTehranIran
  3. 3.Department of Neuroscience, School of Advanced Technologies in MedicineTehran University of Medical SciencesTehranIran
  4. 4.Cognitive and Neuroscience research Center (CNRC)Islamic Azad University, Tehran Medical Sciences BranchTehranIran
  5. 5.Legal Medicine CenterTehranIran
  6. 6.Department of Periodontics, Tehran Dental BranchIslamic Azad UniversityTehranIran
  7. 7.Department of Pharmacology, School of MedicineTehran University of Medical SciencesTehranIran

Personalised recommendations